Skip to main content
Caplight Logo









MimeCure

MimeCure

Private
EeldeCybersecurityhttps://www.mimecure.com/

Last Round

Debt

Jan 1, 2026

Total Funding Raised

$220,000

Momentum

Top 25%

of companies Caplight tracks

Company Overview

MimeCure is a biotechnology company developing a first-in-class regenerative therapy for chronic and progressive lung diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD).

Sector

Cybersecurity

Verticals

Email Security, Data Protection, Cloud Security, Compliance & Risk

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

inhalable regenerative therapylung disease treatmentCOPD therapyIPF therapyprotein therapeuticregenerative therapydrug candidatebiologic druginhalation formulationclinical-stage biotechdrug developmentbiotechnology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MimeCure Comparables

Compare MimeCure with similar companies based on industry and business-model similarity.

No public comparables are available for MimeCure. Request access to learn about comparables coverage.

Request access

MimeCure Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJan 1, 2026
GrantDec 1, 2025
VC RoundNov 1, 2024
GrantOct 23, 2024

MimeCure Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 617% MoM, from 132 to 947.

  • Jan 1, 2026

    Secured debt financing from Netherlands Organization for Scientific Research.

Recent news

Latest coverage and updates

  • receives_awardSep 23, 2026

    MimeCure BV received award LIFE Science Innovation Award at LIFE Science Conference on Sep 22nd '26.

MimeCure Filings

Explore SEC and related filing metadata, where available.

MimeCure filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MimeCure's valuation, stock price, and market status.

Is MimeCure a public or private company?

MimeCure is a private company.

What is the current stock price of MimeCure?

MimeCure is a private company with no public stock price. No recent secondary market data is available.

How much is MimeCure worth (valuation)?

Valuation information for MimeCure is not publicly available.

Can I buy MimeCure stock?

MimeCure shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was MimeCure's last funding round?

MimeCure's most recent funding round was Debt on January 1, 2026.

Who are the main investors in MimeCure?

Key investors in MimeCure include Pharma Connect Capital.

Will MimeCure IPO soon?

No public IPO plans have been announced for MimeCure.

How can I track MimeCure secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MimeCure's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersEelde
Employee Range1
Year Founded2024
Last FundingJan 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?